tirzepatide weight loss nejm for Heart Failure with Preserved Ejection Fraction and Obesity endocrinology #clinicaltrials | NEJM Group

Body aches during tirzepatide therapy typically result from rapid metabolic shifts, dehydration, electrolyte imbalance, or changes in how your joints and muscles support your shifting body weight

2022;38(10):e00300721

Reduced glutathione (GSH): 400 mg per capsule Glutathione is a tripeptide made of three amino acids: cysteine, glutamic acid and glycine

Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI 30 or 27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks

Well-researched in its benefits for general health, more recent conversations have emphasised its use for weight loss and skin improvement

Subsequently, varying amounts of GSH (stock solution 3mM